8-K: Sight Sciences Secures Medicare Pricing for TearCare

Sight Sciences announced that two Medicare Administrative Contractors established jurisdiction-wide pricing for its TearCare dry eye procedure, covering 10.4 million lives.

Summary

• Two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. and First Coast Service Options, Inc., established jurisdiction-wide pricing for CPT code 0563T, which describes the TearCare System procedure.
• The established Medicare fee schedule amount for CPT code 0563T is $1,141.59, effective for dates of service on and after January 1, 2025.
• These two MACs cover states and regions with an estimated 10.4 million total covered lives, representing approximately 30% of the total Medicare fee-for-service covered lives.
• Novitas Solutions, Inc. covers Arkansas, Colorado, District of Colombia, Delaware, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania, and Texas (8.0 million covered lives).
• First Coast Service Options, Inc. covers Florida, Puerto Rico, and the Virgin Islands (2.4 million covered lives).
• TearCare procedure claims will be payable by First Coast and Novitas based on individual medical necessity determinations.
• The company plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call, taking into account these new factors.
• The previous full year 2025 revenue guidance was $72.0 to $76.0 million, with adjusted operating expenses of $95.0 to $99.0 million, assuming approximately $1.0 million for the Dry Eye segment.

Sentiment

Score: 9

Explanation: The establishment of jurisdiction-wide Medicare pricing for TearCare by two major MACs is a highly significant positive development. It provides a clear reimbursement pathway for a key product in a large, underserved market, substantially de-risking its commercialization and opening up significant revenue potential. This is a strong validation of the product and a major catalyst for the company.

Positives

• Established jurisdiction-wide Medicare pricing for the TearCare procedure by two significant MACs provides a clear reimbursement pathway.
• The fee schedule amount of $1,141.59 per procedure is a substantial reimbursement rate.
• Coverage for an estimated 10.4 million Medicare beneficiaries significantly expands market access for TearCare.
• The effective date of January 1, 2025, means the pricing is retroactive for services rendered this year.
• This development validates TearCare as an important interventional dry eye treatment for Medicare beneficiaries.
• The company expects to update its financial guidance positively to reflect this new market access.

Risks

• Payment for TearCare procedures is based on individual medical necessity determinations, which could vary.
• The company's ability to successfully engage with additional third-party payors, clinical societies, and other stakeholders to expand market access beyond current MACs.
• Actual results, performance, or achievements may differ materially from forward-looking statements due to various risks and uncertainties, including those discussed in SEC filings.
• The established local fee schedules are expected to be published on MAC websites, but the timing or completeness of this publication is not guaranteed.

Future Outlook

The company plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call, reflecting the new market access for TearCare in Novitas and FCSO regions. It also intends to continue engaging with third-party payors, clinical societies, and other stakeholders to further support patient access for the TearCare procedure.

Management Comments

• "We are pleased that the rigorous TearCare review conducted by Novitas and First Coast Service Options resulted in established pricing for TearCare. We want to thank our eyecare providers, national and state societies, and Novitas and First Coast Service Options for their work to allow access to this important interventional dry eye treatment for Medicare beneficiaries in these areas when deemed medically necessary by their eyecare provider."
• "We plan to continue to engage with third-party payors, clinical societies, and other stakeholders in continued support of patient access for the TearCare procedure."

Industry Context

Dry eye disease (DED), particularly meibomian gland disease (MGD), affects millions of people, with up to 86% of DED associated with MGD. The current market for dry eye treatments, valued at $1.7 billion in 2024, is largely dominated by eyedrops that do not address the underlying causes of MGD. TearCare aims to establish a new category for reimbursed interventional dry eye treatment, addressing a significant unmet need for an interventional standard of care for MGD. This reimbursement decision by MACs represents a critical step in shifting the treatment paradigm towards interventional solutions for MGD.

Comparison to Industry Standards

• The SAHARA Randomized Controlled Trial (RCT) demonstrated TearCare's statistical superiority in its primary signs endpoint (tear breakup time, TBUT) compared to Restasis, a leading prescription eyedrop.
• TearCare was shown to be non-inferior to Restasis in the ocular surface disease index (OSDI) in the SAHARA RCT.
• A budget impact analysis indicated that a 20% market share increase for TearCare compared to Restasis could lead to savings of approximately $37 million per year for an insurance plan with 1 million covered lives, suggesting cost-effectiveness for payors.
• The OLYMPIA RCT compared TearCare to LipiFlow, another thermal pulsation device, indicating TearCare's competitive positioning in the interventional MGD treatment space.

Stakeholder Impact

• **Shareholders:** Potential for increased revenue, improved financial outlook, and positive share price movement due to expanded market access and clear reimbursement for a key product.
• **Eyecare Providers:** Clearer reimbursement pathway for the TearCare procedure, potentially leading to increased adoption and utilization of the system for treating MGD.
• **Medicare Beneficiaries:** Enhanced access to an interventional dry eye treatment (TearCare) for those with medical necessity in the covered regions.
• **Payors:** Budget impact analysis suggests potential cost savings compared to alternative treatments like Restasis, aligning with payor priorities for cost-effective solutions.

Next Steps

• The company plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call.
• The established local fee schedules are expected to be published on the Novitas and FCSO websites for reference by eyecare providers.
• The company plans to continue engaging with third-party payors, clinical societies, and other stakeholders to support patient access for the TearCare procedure.

Key Dates

Recommendation

The establishment of jurisdiction-wide Medicare pricing for TearCare by two major MACs, covering 10.4 million lives at a fee of $1,141.59 per procedure, is a transformative event for Sight Sciences. This development provides a clear and substantial reimbursement pathway for a product addressing the root cause of a highly prevalent condition (MGD-associated dry eye disease) that has historically lacked an interventional standard of care. The retroactive effective date to January 1, 2025, further enhances the immediate financial impact. This significantly de-risks the commercialization of TearCare in these regions and opens up a large, previously underserved market segment. The company's intention to update its financial guidance to reflect this market access underscores the expected positive impact on future revenue and profitability. This catalyst positions Sight Sciences for accelerated growth and market penetration, making it a compelling 'strong buy' for investors seeking exposure to innovative medical technologies with expanding reimbursement.

Keywords

Sight Sciences, TearCare, Medicare, Reimbursement, CPT code 0563T, Dry Eye Disease, Meibomian Gland Dysfunction, Medical Device, Ophthalmology, Novitas Solutions, First Coast Service Options